(Q34535479)

2 August 2017

1 reference

title

The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs (English)

1 reference

2 August 2017

Giuseppe Borgheini

1

1 reference

2 August 2017

publication date

1 June 2003

1 reference

2 August 2017

published in

Clinical Therapeutics

1 reference

2 August 2017

volume

25

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

1578-1592

1 reference

Is generic prescribing acceptable in epilepsy?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Low-dose oral contraceptives: health consequences of discontinuation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Subtherapeutic INR values associated with a switch to generic warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Impact of generic substitution of anticonvulsants on the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Generic substitutions for antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Drug substitution in transplantation: a National Kidney Foundation White Paper

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Recurrence of ventricular tachycardia after conversion from proprietary to generic procainamide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Pharmacological effects of antiarrhythmic drugs. Review and update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Generic prescribing for epilepsy. Is it safe?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Comparative bioavailability of a generic phenytoin and Dilantin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Comparative bioavailability of phenytoin from generic formulations in the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Bio-availability and dissolution of three phenytoin preparations for children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Double-blind randomized study comparing brand-name and generic phenytoin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Loss of seizure control associated with generic substitution of carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

The bioinequivalence of carbamazepine tablets with a history of clinical failures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Therapeutic bioequivalency study of brand name versus generic carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Effects of switching from Depakene to generic valproic acid on individuals with mental retardation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Gastrointestinal side-effects after switch to generic valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Bioinequivalence of a generic brand of diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980157-1

7 January 2021

10.1016/S0149-2918(03)80157-1

Identifiers

DOI

1 reference

2 August 2017

1 reference